Development of an Australasian Dermatology Registry
Skin disorders rank sixth in the non-fatal burden of disease within Australia and fourth worldwide. Despite this burden of disease for skin conditions, local data pertaining to the management, treatment, outcomes and quality of life of this patient group are limited. The Australasian Dermatology Registry will monitor and evaluate current and emerging therapies, provide real world evidence on the impact skin disorders have on patients living with these conditions and provide a platform for dermatology research.
Authors
- Peter Foley (ORCID: https://orcid.org/0000-0001-5891-5607)
- Christopher Baker (ORCID: https://orcid.org/0009-0003-0144-2927)
- Julie Buckner Armstrong
Institutions
- The University of Melbourne (AU)
- St Vincent's Hospital Melbourne (AU)
- Skin Health Institute (AU)
Publication Details
- Journal
- Australasian Journal of Dermatology
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1111/ajd.14468
- Primary Topic
- Eosinophilic Disorders and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Novartis
- Sanofi
- Teva Pharmaceutical Industries
- Celgene
- AbbVie
- Boehringer Ingelheim
- Regeneron Pharmaceuticals
- Valeant Pharmaceuticals International
- Dermira
- Incyte
- Argenx
- Galderma
- Sun Pharma
- LEO Pharma
- Genentech
- Johnson and Johnson
- Eli Lilly Australia
- UCB Pharma